Shenzhen Neptunus Changjian Pharmaceutical Co., Ltd.

Neptunus Group was founded in 1989. After more than 30 years of development, Neptunus has grown from a small enterprise into a large enterprise group with sales exceeding 10 billion yuan. It has also actively undertaken social responsibilities and made important contributions to the development of the pharmaceutical industry and the national economy and society. Shenzhen Neptunus Group Co., Ltd., founded in 1989, is a large enterprise group with competitive advantages across the entire pharmaceutical industry chain in China. Over more than 20 years of development, Neptunus Group has adhered to a people-oriented approach, innovated its development model, and built a harmonious enterprise, achieving sustained and rapid growth. In 2010, Neptunus Group's sales exceeded 13 billion yuan, maintaining rapid growth for many consecutive years. For more than 30 years, Neptunus Group has focused on the development of the pharmaceutical industry, continuously enhanced its independent innovation capability, and built competitive advantages across the entire pharmaceutical industry chain. It has now formed a complete industry chain covering pharmaceutical product research and development, pharmaceutical manufacturing, pharmaceutical commercial distribution, and chain retail, and has developed relatively obvious competitive advantages in major links such as brand, research and development, manufacturing, logistics, and retail. The Group has three listed companies in Shenzhen, Hong Kong, and the United States, and possesses a most valuable brand in China's pharmaceutical industry, the largest domestic pharmaceutical retail network, and a leading independent innovation system for pharmaceutical products. Its operating performance has maintained sustained and rapid growth for many consecutive years. In 2010, Neptunus Group had total assets of 10.3 billion yuan, achieved sales revenue of 11.1 billion yuan, and paid taxes of 380 million yuan. It has become a large private pharmaceutical enterprise in China's pharmaceutical industry with a complete industry chain, prominent competitive advantages, a leading industry position, and a relatively high degree of internationalization. For more information, please visit the website: *